[6-K] Haoxi Health Technology Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haoxi Health Technology Limited held an extraordinary general meeting where shareholders approved a major share capital reduction and related governance changes. The authorised share capital will be reduced and reorganized from US$35,200,000,000,000 (par value US$0.32 per share) to US$11,000,000 (par value US$0.0000001 per share) for both Class A and Class B ordinary shares, subject to Companies Act requirements. The share capital reduction was approved with 10,000,995 votes for, 7,952 against and 12 abstentions. Shareholders also approved the Ninth Amended Memorandum and Articles of Association and the adjournment resolution by similar vote margins. Holders of 472,049 Class A shares and all 317,897 Class B shares participated, meeting the quorum requirement.

Key Figures

Authorised capital before change: US$35,200,000,000,000 Authorised capital after change: US$11,000,000 Old par value per share: US$0.32 +5 more

8 metrics

Authorised capital before change US$35,200,000,000,000 Authorised share capital before reduction

Authorised capital after change US$11,000,000 Authorised share capital after reduction and reorganisation

Old par value per share US$0.32 Par value for Class A and B shares before change

New par value per share US$0.0000001 Par value for Class A and B shares after change

Votes for capital reduction 10,000,995 votes Share capital reduction resolution

Votes against capital reduction 7,952 votes Share capital reduction resolution

Class A shares voted 472,049 shares Out of 1,904,632 Class A shares issued and outstanding

Class B shares voted 317,897 shares All Class B shares issued and outstanding

Key Terms

extraordinary general meeting, Share Capital Reduction, authorised share capital, par value, +1 more

5 terms

extraordinary general meeting financial

"held an extraordinary general meeting of shareholders (the “EGM”) in person"

Share Capital Reduction financial

"by the taking of the following steps (together, the “Share Capital Reduction”)"

authorised share capital financial

"the authorised share capital of the Company be reduced and reorganized"

The maximum number of shares a company is legally allowed to create under its founding documents. Think of it like the size of an empty container: it sets the upper limit on how many ownership pieces the company can hand out, which matters to investors because it controls how easily a company can raise cash, dilute existing owners, or change voting power without a formal legal change.

par value financial

"Class A Ordinary Shares of par value US$0.32 each and 10,000,000,000,000 Class B Ordinary Shares of par value US$0.32 each"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

Ninth Amended M&AA financial

"Accordingly, the Ninth Amended M&AA has been approved and adopted."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/06/2026 - 04:16 PM Accepted by SEC EDGAR 07/06/2026 - 04:15 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-41933

Haoxi Health Technology Limited

Room 801, Tower C, Floor 8, Building 103, Huizhongli, Chaoyang District

Beijing, China

+86-10-13311587976

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒    Form 40-F ☐

Submission of Matters to a Vote of Security Holders.

Haoxi Health Technology Limited (the “Company”) held an extraordinary general meeting of shareholders (the “EGM”) in person at Room 801, Tower C, Floor 8, Building 103, Huizhongli, Chaoyang District, Beijing, China on July 6, 2026 at 9:30AM Eastern Time. Shareholders of the Company’s Class A ordinary shares (the “Class A Ordinary Shares”) and Class B ordinary shares (the “Class B Ordinary Shares”) voted by proxy or at the meeting. Holders of 472,049 out of a total of 1,904,632 Class A Ordinary Shares issued and outstanding, and holders of 317,897 out of a total of 317,897 Class B Ordinary Shares issued and outstanding voted at the EGM in person or by proxy. More than one-third (1/3) of the Class A Ordinary Shares and Class B Ordinary Shares, voting together as a single class, entitled to vote at the EGM are represented in person or by proxy, and a quorum for the transaction of business was present at the Meeting. Each Class A Ordinary Share is entitled to one (1) vote and each Class B Ordinary Share is entitled to thirty (30) votes. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

1. The vote on the special resolution was as follows:

that subject to all further requirements prescribed by sections 14, 14A and 14B of the Companies Act (Revised) relating to share capital reductions being complied with, the authorised share capital of the Company be reduced and reorganized from US$35,200,000,000,000 divided into 100,000,000,000,000 Class A Ordinary Shares of par value US$0.32 each and 10,000,000,000,000 Class B Ordinary Shares of par value US$0.32 each to US$11,000,000 divided into 100,000,000,000,000 Class A Ordinary Shares of par value US$0.0000001 each and 10,000,000,000,000 Class B Ordinary Shares of par value US$0.0000001 each by the taking of the following steps (together, the “Share Capital Reduction”):

(a) the par value of each issued and outstanding Class A Ordinary Share of par value US$0.32 each and each issued and outstanding Class B Ordinary Share of par value US$0.32 each in the share capital of the Company being reduced to US$0.0000001 by cancelling US$0.3199999 of the paid-up capital on each of the issued and outstanding Class A Ordinary Shares of par value US$0.32 each and Class B Ordinary Shares of par value US$0.32 each (the “Capital Reduction”), with the amount deemed to be paid up on each issued and outstanding share of the Company to be US$0.0000001 following the Capital Reduction;

(b) the credit arising from the Capital Reduction being transferred to a distributable reserve account of the Company which may be utilized by the Company as the board of directors of the Company (the “Board”) may deem fit and as permitted under the Companies Act (Revised), the Company’s memorandum and articles of association, and all relevant applicable laws, including, without limitation, eliminating or setting off any accumulated losses of the Company (if any) from time to time;

(c) immediately following the Capital Reduction:

(i) each authorized but unissued Class A Ordinary Share of par value US$0.32 being subdivided into 3,200,000 Class A Ordinary Shares of par value US$0.0000001 each; and

(ii) each authorized but unissued Class B Ordinary Share of par value US$0.32 being subdivided into 3,200,000 Class B Ordinary Shares of par value US$0.0000001 each (the “Subdivision”); and

1

(d) immediately following the Subdivision, the authorized share capital of the Company being altered by the cancellation of such number of unissued Class A Ordinary Shares of par value US$0.0000001 and unissued Class B Ordinary Shares of par value US$0.0000001 that will result in the Company having authorized share capital of US$11,000,000 divided into 100,000,000,000,000 Class A Ordinary Shares of par value US$0.0000001 each and 10,000,000,000,000 Class B Ordinary Shares of par value US$0.0000001 each (the “Share Capital Reduction Proposal”).

For		Against		Abstain
10,000,995		7,952		12

Accordingly, the Share Capital Reduction has been approved.

2. The vote on the special resolution, that subject to and immediately following the Share Capital Reduction being effected, the Company adopt ninth amended and restated memorandum and articles of association in the form attached to the notice of meeting as Annex A (the “Ninth Amended M&AA”), in substitution for, and to the exclusion of, the Company’s eighth amended and restated memorandum and articles of association, to reflect the Share Capital Reduction (the “Adoption of the Ninth Amended M&AA Proposal”) was as follows:

For		Against		Abstain
10,001,225		7,690		44

Accordingly, the Ninth Amended M&AA has been approved and adopted.

3. The vote on the ordinary resolution, the Meeting be adjourned to a later date or dates or sine die, if necessary, to permit further solicitation and vote of proxies, if there are not sufficient votes at the time of the Meeting or adjournment or postponement thereof to approve of the foregoing proposals (the “Adjournment”, and such proposal, the “Adjournment Proposal”) was as follows:

For		Against		Abstain
10,001,059		7,888		12

Accordingly, the Adjournment has been approved.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Haoxi Health Technology Limited
Date: July 6, 2026	By:	/s/ Zhen Fan
	Name:	Zhen Fan
	Title:	Chief Executive Officer

3